<DOC>
	<DOC>NCT02138890</DOC>
	<brief_summary>This double-blind, multicenter, randomized, controlled trial (RCT) will evaluate the efficacy of a single dose of Autologous Protein Solution (APS) in patients with osteoarthritis (OA) of the knee who have failed at least 1 conservative osteoarthritis (OA) therapy (e.g. physiotherapy, simple analgesics, intra-articular injection).</brief_summary>
	<brief_title>APSS-33-00: A Multicenter, Pilot Study of Autologous Protein Solution (APS) in Knee Osteoarthritis (OA)</brief_title>
	<detailed_description>A double-blind, multicenter, randomized, controlled trial (RCT) that will evaluate the efficacy of a single dose of Autologous Protein Solution (APS) in patients with Osteoarthritis (OA) of the knee who have failed at least 1 conservative OA therapy (e.g. physiotherapy, simple analgesics, intra-articular injection).</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis, Knee</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Male or female ≥40 years and ≤75 years. Willingness and ability to comply with the study procedures and visit schedules and ability to follow verbal and written instructions. Diagnosis of knee osteoarthritis (OA) Grade 2 or 3 according to the KellgrenLawrence scale Body mass index (BMI) ≤ 40. Failed at least 1 conservative OA therapy Signed an independent ethics committee (IEC) approved informed consent form (ICF). Intraarticular Hyaluronic (HA) injection within 6 months</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Autologous Protein Solution</keyword>
	<keyword>APS</keyword>
	<keyword>Osteoarthritis</keyword>
	<keyword>Intra Articular Injection</keyword>
</DOC>